Active, not recruitingPhase 1NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Studying Gonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Toray Industries, Inc
- Intervention
- TRK-950(biological)
- Enrollment
- 138 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (14)
- HonorHealth Research Institute, Scottsdale, Arizona, United States
- AOA-HOPE, Tucson, Arizona, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- HOAG Memorial Hospital Presbyterian, Newport, California, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Atlantic Health System, Morristown, New Jersey, United States
- Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center), Eugene, Oregon, United States
- Northwest Cancer Specialists, Portland, Oregon, United States
- Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
- Texas Oncology - Downtown Fort Worth Cancer Center, Fort Worth, Texas, United States
- Virginia Cancer Specialists, PC, Leesburg, Virginia, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Centre Léon Bérard, Lyon, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03872947 on ClinicalTrials.govOther trials for Gonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc.
- RECRUITINGNCT05645510LIVInG With chrONic Cancer TrEatments (LONGEVITI) StudyUniversity of Alberta
- RECRUITINGNANCT05142982Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced SeminomaTata Memorial Centre
- RECRUITINGNANCT05053230A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04752826BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BioInvent International AB
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04205227ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsENB Therapeutics, Inc
- RECRUITINGNANCT03787056Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon
- ACTIVE NOT RECRUITINGNANCT03418844Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of ChemotherapyCentre Francois Baclesse